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diovascular diseases (log-OR  0.7488, S.E.  0.0912).
The overdispersion parameters for the NB model and the
two-part NB model were 0.3929 and 1.3796 respec-
tively, indicating the necessity of applying a two-part
model. CONCLUSION: Our data support the hypothesis
that there is individual heterogeneity for risk of hospital-
ization and a “healthy” sub-population of patients with
Type 2 diabetes. Consequently we recommend applica-
tion of two-part models that first predicts the risk of any
hospitalization for each individual in the population and
then predicts the likely number of hospitalizations sepa-
rately for high and low risk sub-populations.
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OBJECTIVE: For cost-benefit analysis, health technolo-
gies with multiple effects should theoretically be valued
in a single scenario by a holistic willingness-to-pay (WTP)
measure. Recently, decomposed scenarios in which re-
spondents state their WTP for each individual effect were
used more often. Evidence can be found that the sum of
such decomposed WTPs overestimates the holistic WTP,
i.e. the holistic WTP is subadditive. No theoretically
founded and empirically validated aggregation function
for decomposed WTPs exists. Our aims were to derive
such an aggregation function and to test it empirically.
METHODS: Within an expected utility model, we identi-
fied risk aversion with respect to money and a positive
correlation of better health and marginal utility of money
as reasons for subadditivity. Under mutual utility inde-
pendence of health and money, we derived a theoretically
founded aggregation function covering these two im-
pacts. For an empirical application of this function, one
has to determine the utilities of the health states, of well-
defined states “rich&ill” and “poor&healthy”, and a
utility function over money—beside the decomposed
WTPs. In a contingent valuation study, we asked 92 pa-
tients with diabetes to state their WTP for reductions in
the risk of several diabetic complications in decomposed
and holistic scenarios. Utilities were measured by standard
gamble procedures. 46 patients (group 1) valued two com-
plications (diabetic retinopathy & neuropathy). The re-
maining 46 patients (group 2) valued also a third compli-
cation (diabetic foot). RESULTS: Subadditivity occurred
in both groups, but was not statistically significant. The
sum of decomposed WTPs overestimated holistic WTP by
8.3% in group 1 and 16% in group 2. Theoretically
founded aggregation underestimated holistic WTP by 2%
in group 1 and 1.2% in group 2. CONCLUSIONS: The
results of our pilot study suggest that the theoretically
founded aggregation function might overcome problems
of subadditivity, which can be economically relevant. Fur-
ther empirical testing of the approach is indicated.
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OBJECTIVE: To measure whether more rapid transition
toward insulin therapy in newly diagnosed Type II dia-
betic patients improves blood glucose control (BGC) and
reduces risk of diabetic related complications (DC).
METHODS: We used longitudinal data obtained from
IMS Mediplus UK to identify patients newly diagnosed
with Type II diabetes between November 1, 1993 and
October 31, 1994. Newly diagnosed was defined as no
prior diagnosis or use of anti-diabetic agents. Patient data
for five years included demography, laboratory values
(Hb1Ac), treatment, DC and comorbidities. Patients were
assigned to an initial treatment modality including diet
and exercise (DE), sulfonylureas (S), anti-hyperglycemics
(A), a combination (C), insulin (I), or insulin plus an oral
agent (IO). Each stepwise transition in treatment, Hb1Ac
readings and manifestations of DC were tracked for at
least five years. Generalized Estimating Equations (GEE)
estimated the expected reduction in Hb1Ac as patients
transitioned to insulin sooner while controlling for base-
line Hb1Ac and initial treatment assignment. Logistic re-
gression was used to estimate the change in risk of DC
associated with reductions in Hb1Ac and accelerated
transitioning toward insulin treatment. RESULTS: 2,137
patients were eligible for analysis. By initial treatment pa-
tients were allocated as follows: 1,894 (DE), 200 (S), 30
(A), 10 (C), 3 (I), and 0 (IO). Stepwise patients transitioned
toward insulin with 180 patients by year 5. A total of 49
patients (2.3%) had at least one DC after controlling for
baseline. Hb1Ac was reduced by 0.0037 (P  0.001) for
each day sooner the patient was transitioned toward insu-
lin therapy or a reduction of 1.0 in Hb1Ac (12.5%) can be
expected if transitioned within 270 days. Logistic results in-
dicated that transitioning toward insulin therapy by day
270 yields a reduction in risk of DC of 0.388% (P  0.01).
CONCLUSION: Sooner transitioning to insulin therapy
improves BGC and reduces the risk of complications.
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OBJECTIVE: To measure the willingness to pay (WTP)
for a reduction in the number of micturitions and urinary
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leakages of Overactive Bladder (OAB) patients with urge
incontinence. METHODS: A questionnaire was adminis-
tered to 388 patients identified in six areas in Italy. This
questionnaire was divided into 3 sections: socio-eco-
nomic characteristics and severity of symptoms; health
related quality of life; close-ended Contingent Valuation
question about the prices of a drug and the reduction of
symptoms on a monthly base. The answers were ana-
lyzed by regression analysis, both with a univariate and a
multivariate logistic model. A stepwise procedure was
used to select the variables affecting the probability to
answer yes to the WTP question. RESULTS: The final re-
gression model included the price, sex, income and vital-
ity as significant independent variables. The mean WTP
per month based on the final logistic model was Lit.
229.000 ($US115) for men and Lit. 153.000 ($US77) for
women; the median WTP was Lit. 220.000 ($US110) for
men and Lit. 132.000 ($US66) for women. CONCLU-
SION: The patients with incontinence problems are will-
ing to pay amounts higher than any drug therapy cost
available on the market for a reduction in the number of
micturitions and leakages. Furthermore, vitality was the
highly correlated factor between health related quality of
life parameters.
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OBJECTIVE: The aim of this study is to compare health
care workers’ perceptions on the quality of life (QoL) af-
ter renal transplantation (RTX) with expectations of
RTX candidates and actual QoL of RTX patients.
METHODS: A comparative study design was used for
the comparison of health care workers’ perceived and pa-
tients’ expected and actual QoL after RTX. The EQ-5D
self-report questionnaire was used as QoL measure.
Health state descriptions as well as valuations on a visual
analogue scale (VAS) were collected. Sixty-two RTX can-
didates were surveyed and followed longitudinally from
November 1999 until May 2000. Twelve patients were
transplanted and surveyed again two weeks after dis-
charge from hospital. All health care workers (N  123)
had regular contact with dialysis or RTX patients. “Raw”
VAS scores were analysed as well as EQ index scores as-
signed to health state descriptions from patients and
health care workers. Given the non-normality of the
data, non-parametric tests were used for statistical analy-
ses. RESULTS: Preliminary results show that health care
workers’ perceptions on QoL after RTX were signifi-
cantly lower than patients’ expectations (P  0.0005).
Two weeks after discharge, the twelve transplanted pa-
tients showed moderate improvement in VAS scores for
actual health pre- to post-transplantation (P  0.05).
Pre-transplant QoL expectations were not (yet?) fulfilled
for most patients. Finally, transplant nurses’ valuations
were closer to patients’ actual QoL after transplantation
(P  0.20) than nurses’ on other wards. CONCLU-
SIONS: The preliminary results are based on a small
sample of patients. As patients will be followed-up fur-
ther in the future (at 4, 8 and 12 months after RTX) and
more patients will be included, more results will be avail-
able to show how patients’ actual QoL evolves after RTX
and how this evolution compares to their expectations
before transplantation. These results will be presented at
the meeting.
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OBJECTIVES: To study the cost-effectiveness of Helico-
bacter pylori eradication therapy on patients receiving
NSAID treatment for musculoskeletal pain from the per-
spective of a public health organization. A randomized,
controlled clinical trial was conducted previously in a
teaching hospital in Hong Kong and it showed positive
effects of H. pylori eradication therapy in the prevention
of NSAID-induced peptic ulcers. METHODS: A decision
tree was designed to analyse the cost-effectiveness of H.
pylori eradication in the prevention of NSAID-induced
peptic ulcers. Probabilities and costs data were estimated
from the randomized controlled clinical trial. Patients
with musculoskeletal disorders and H. pylori infection
but no pre-existing ulcers were randomly assigned to
naproxen alone (750mg od) for 8 weeks or a 1-week
treatment of triple therapy (bismuth subcitrate 120mg,
tetracycline 500mg, metronidazole 400mg, po qid) be-
fore naproxen 750mg od. Endoscopic assessment was
performed after 8 weeks of NSAID treatment. The primary
endpoint was endoscopy-confirmed gastric or duodenal
ulcers. The targeted direct medical costs included the cost
for H. pylori eradication and the cost for peptic ulcer
management. RESULTS: One hundred patients were re-
cruited and 92 completed the trial (47 in the naproxen
group and 45 in the triple-therapy group). The medical
records of the 92 patients who completed the study were
reviewed. Three of the 45 patients (7%) in the triple-ther-
apy group and 12 of 47 patients (26%) in the naproxen
group developed peptic ulcers. The total direct medical
costs (including costs of peptic ulcer management) per
patients for the triple-therapy group and naproxen group
